Literature DB >> 28161533

Prevalence, determinants and clinical correlates of vitamin D deficiency in patients with Chronic Obstructive Pulmonary Disease in London, UK.

David A Jolliffe1, Wai Yee James2, Richard L Hooper2, Neil C Barnes3, Claire L Greiller2, Kamrul Islam2, Angshu Bhowmik4, Peter M Timms4, Raj K Rajakulasingam4, Aklak B Choudhury5, David E Simcock6, Elina Hyppönen7, Robert T Walton2, Christopher J Corrigan8, Christopher J Griffiths9, Adrian R Martineau10.   

Abstract

Vitamin D deficiency is common in patients with chronic obstructive pulmonary disease (COPD), yet a comprehensive analysis of environmental and genetic determinants of serum 25-hydroxyvitamin D (25[OH]D) concentration in patients with this condition is lacking. We conducted a multi-centre cross-sectional study in 278 COPD patients aged 41-92 years in London, UK. Details of potential environmental determinants of vitamin D status and COPD symptom control and severity were collected by questionnaire, and blood samples were taken for analysis of serum 25(OH)D concentration and DNA extraction. All participants performed spirometry and underwent measurement of weight and height. Quadriceps muscle strength (QS) was measured in 134 participants, and sputum induction with enumeration of lower airway eosinophil and neutrophil counts was performed for 44 participants. Thirty-seven single nucleotide polymorphisms (SNP) in 11 genes in the vitamin D pathway (DBP, DHCR7, CYP2R1, CYP27B1, CYP24A1, CYP27A1, CYP3A4, LRP2, CUBN, RXRA, and VDR) were typed using Taqman allelic discrimination assays. Linear regression was used to identify environmental and genetic factors independently associated with serum 25(OH)D concentration and to determine whether vitamin D status or genetic factors independently associated with % predicted forced expiratory volume in one second (FEV1), % predicted forced vital capacity (FVC), the ratio of FEV1 to FVC (FEV1:FVC), daily inhaled corticosteroid (ICS) dose, respiratory quality of life (QoL), QS, and the percentage of eosinophils and neutrophils in induced sputum. Mean serum 25(OH)D concentration was 45.4nmol/L (SD 25.3); 171/278 (61.5%) participants were vitamin D deficient (serum 25[OH]D concentration <50nmol/L). Lower vitamin D status was independently associated with higher body mass index (P=0.001), lower socio-economic position (P=0.037), lack of vitamin D supplement consumption (P<0.001), sampling in Winter or Spring (P for trend=0.006) and lack of a recent sunny holiday (P=0.002). Vitamin D deficiency associated with reduced % predicted FEV1 (P for trend=0.060) and % predicted FVC (P for trend=0.003), but it did not associate with FEV1:FVC, ICS dose, QoL, QS, or the percentage of eosinophils or neutrophils in induced sputum. After correction for multiple comparisons testing, genetic variation in the vitamin D pathway was not found to associate with serum 25(OH)D concentration or clinical correlates of COPD severity. Vitamin D deficiency was common in this group of COPD patients in the UK, and it associated independently with reduced % predicted FEV1 and FVC. However, genetic variation in the vitamin D pathway was not associated with vitamin D status or severity of COPD.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  COPD; FEV1; FVC; Single nucleotide polymorphism; Spirometry; Vitamin D

Mesh:

Substances:

Year:  2017        PMID: 28161533     DOI: 10.1016/j.jsbmb.2017.01.019

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  8 in total

1.  Nutrition as a modifiable factor in the onset and progression of pulmonary function impairment in COPD: a systematic review.

Authors:  Lieke E J van Iersel; Rosanne J H C G Beijers; Harry R Gosker; Annemie M W J Schols
Journal:  Nutr Rev       Date:  2022-05-09       Impact factor: 6.846

2.  Associations Among 25-Hydroxyvitamin D Levels, Lung Function, and Exacerbation Outcomes in COPD: An Analysis of the SPIROMICS Cohort.

Authors:  Robert M Burkes; Agathe S Ceppe; Claire M Doerschuk; David Couper; Eric A Hoffman; Alejandro P Comellas; R Graham Barr; Jerry A Krishnan; Christopher Cooper; Wassim W Labaki; Victor E Ortega; J Michael Wells; Gerard J Criner; Prescott G Woodruff; Russell P Bowler; Cheryl S Pirozzi; Nadia N Hansel; Robert A Wise; Todd T Brown; M Bradley Drummond
Journal:  Chest       Date:  2020-01-17       Impact factor: 9.410

3.  Vitamin D status is associated with muscle strength and quality of life in patients with COPD: a seasonal prospective observation study.

Authors:  Emma L Carson; L Kirsty Pourshahidi; Sharon M Madigan; Francina R Baldrick; Martin G Kelly; Eamon Laird; Martin Healy; J J Strain; Maria S Mulhern
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-08-28

4.  Correlation of severity of chronic obstructive pulmonary disease with serum vitamin-D level.

Authors:  Ummul Baneen; Sufia Naseem
Journal:  J Family Med Prim Care       Date:  2019-07

5.  Vitamin D supplementation in chronic obstructive pulmonary disease patients with low serum vitamin D: a randomized controlled trial.

Authors:  Rachida Rafiq; Floor E Aleva; Jasmijn A Schrumpf; Johannes M Daniels; Pierre M Bet; Wim G Boersma; Paul Bresser; Michiel Spanbroek; Paul Lips; Tim J van den Broek; Bart J F Keijser; André J A M van der Ven; Pieter S Hiemstra; Martin den Heijer; Renate T de Jongh
Journal:  Am J Clin Nutr       Date:  2022-08-04       Impact factor: 8.472

6.  The Dietary Inflammatory Index and Early COPD: Results from the National Health and Nutrition Examination Survey.

Authors:  Chen Chen; Ting Yang; Chen Wang
Journal:  Nutrients       Date:  2022-07-11       Impact factor: 6.706

Review 7.  Perspective: improving vitamin D status in the management of COVID-19.

Authors:  Maryam Ebadi; Aldo J Montano-Loza
Journal:  Eur J Clin Nutr       Date:  2020-05-12       Impact factor: 4.016

Review 8.  Clinical Significance of Analysis of Vitamin D Status in Various Diseases.

Authors:  Magdalena Kowalówka; Anna K Główka; Marta Karaźniewicz-Łada; Grzegorz Kosewski
Journal:  Nutrients       Date:  2020-09-11       Impact factor: 5.717

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.